Pharmaceutical

BioCryst Pharmaceuticals (NASDAQ:BCRX) announced today the dosing of the first patient into APeX-2, a Phase 3 clinical trial evaluating two dosage strengths of BCX7353 administered orally once-daily (QD)  as a preventive treatment to reduce the frequency of attacks in patients with hereditary angioedema (HAE). As quoted in the press release: “The ability to safely prevent attacks …

BioCryst Pharmaceuticals (NASDAQ:BCRX) announced today the dosing of the first patient into APeX-2, a Phase 3 clinical trial evaluating two dosage strengths of BCX7353 administered orally once-daily (QD)  as a preventive treatment to reduce the frequency of attacks in patients with hereditary angioedema (HAE).

As quoted in the press release:

“The ability to safely prevent attacks of angioedema with an oral medicine has been a dream for many HAE patients.  Today marks a significant milestone toward the realization of that dream,” said Bruce Zuraw, MD and Principal Investigator of the APeX-2 trial. “I am excited to be able to participate in this important trial, which we believe will lead to an effective oral prophylactic treatment offering HAE patients the opportunity to lead a normal life.”

Click here to read the full press release.

MARKETS

Markets
TSX19577.04+31.10
TSXV660.08+4.88
DOW32726.82-85.68
S&P 5004151.94-3.23
NASD12720.58+52.42
ASX6975.90-22.20

COMMODITIES

Commodities
Gold1791.05+27.43
Silver20.18+0.19
Copper3.47+0.01
Palladium2065.50+70.50
Platinum931.50+34.50
Oil87.77-2.89
Heating Oil3.29-0.13
Natural Gas8.14-0.13

DOWNLOAD FREE REPORTS

×